DE3856160T2 - Redoxsystem für auf das Gehirn gerichtete Arzneimittelabgabe - Google Patents

Redoxsystem für auf das Gehirn gerichtete Arzneimittelabgabe

Info

Publication number
DE3856160T2
DE3856160T2 DE3856160T DE3856160T DE3856160T2 DE 3856160 T2 DE3856160 T2 DE 3856160T2 DE 3856160 T DE3856160 T DE 3856160T DE 3856160 T DE3856160 T DE 3856160T DE 3856160 T2 DE3856160 T2 DE 3856160T2
Authority
DE
Germany
Prior art keywords
brain
redox
systems
drug delivery
redox systems
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE3856160T
Other languages
English (en)
Other versions
DE3856160D1 (de
Inventor
Nicholas S Bodor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Florida
Original Assignee
University of Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Florida filed Critical University of Florida
Application granted granted Critical
Publication of DE3856160D1 publication Critical patent/DE3856160D1/de
Publication of DE3856160T2 publication Critical patent/DE3856160T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/559—Redox delivery systems, e.g. dihydropyridine pyridinium salt redox systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/26—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C219/28—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton having amino groups bound to acyclic carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/08—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to hydrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/16—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/18—Dibenzazepines; Hydrogenated dibenzazepines
    • C07D223/22—Dibenz [b, f] azepines; Hydrogenated dibenz [b, f] azepines
    • C07D223/24—Dibenz [b, f] azepines; Hydrogenated dibenz [b, f] azepines with hydrocarbon radicals, substituted by nitrogen atoms, attached to the ring nitrogen atom
    • C07D223/28—Dibenz [b, f] azepines; Hydrogenated dibenz [b, f] azepines with hydrocarbon radicals, substituted by nitrogen atoms, attached to the ring nitrogen atom having a single bond between positions 10 and 11
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/74—Two oxygen atoms, e.g. hydantoin with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to other ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
    • C07D233/78—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/38—[b, e]- or [b, f]-condensed with six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D499/00—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
DE3856160T 1987-12-30 1988-12-19 Redoxsystem für auf das Gehirn gerichtete Arzneimittelabgabe Expired - Lifetime DE3856160T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/139,755 US5002935A (en) 1987-12-30 1987-12-30 Improvements in redox systems for brain-targeted drug delivery

Publications (2)

Publication Number Publication Date
DE3856160D1 DE3856160D1 (de) 1998-05-14
DE3856160T2 true DE3856160T2 (de) 1998-11-12

Family

ID=22488144

Family Applications (1)

Application Number Title Priority Date Filing Date
DE3856160T Expired - Lifetime DE3856160T2 (de) 1987-12-30 1988-12-19 Redoxsystem für auf das Gehirn gerichtete Arzneimittelabgabe

Country Status (10)

Country Link
US (3) US5002935A (de)
EP (1) EP0327766B1 (de)
JP (1) JP3038715B2 (de)
AT (1) ATE164855T1 (de)
AU (1) AU618995B2 (de)
CA (1) CA1331564C (de)
DE (1) DE3856160T2 (de)
ES (1) ES2118707T3 (de)
IE (1) IE64886B1 (de)
ZA (1) ZA889679B (de)

Families Citing this family (250)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5221695A (en) * 1987-12-22 1993-06-22 Glaxo Group Limited Aqueous formulation containing a piperidinylcyclopentylheptenoic acid derivative and beta-cyclodextrin
US5229370A (en) * 1988-08-15 1993-07-20 Ammeraal Robert N Water soluble branched beta cyclodextrin steroid complex
EP0381747A4 (en) * 1988-08-15 1991-09-11 American Maize-Products Company Water soluble branched beta cyclodextrin steroid complex
US5997856A (en) * 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
US5068227A (en) * 1989-01-18 1991-11-26 Cyclex, Inc. Cyclodextrins as carriers
ATE84205T1 (de) * 1989-03-28 1993-01-15 Duphar Int Res Vorgefuellte injektionsvorrichtung mit einem fass, das mit einer fluessigen diazepam-formulierung gefuellt ist.
US5834445A (en) * 1989-08-11 1998-11-10 Sikorski; Christopher Process for preparing decolorized carotenoid-cyclodextrin complexes
US5344844A (en) * 1990-01-09 1994-09-06 Kabushiki Kaisya Advance Salt excretion promoting composition
GB9001987D0 (en) * 1990-01-29 1990-03-28 Janssen Pharmaceutica Nv Improved cyclodextrin based erythropietin formulation
GB9002375D0 (en) * 1990-02-02 1990-04-04 Pfizer Ltd Triazole antifungal agents
TW282399B (de) * 1990-05-25 1996-08-01 Takeda Pharm Industry Co Ltd
US5124154A (en) * 1990-06-12 1992-06-23 Insite Vision Incorporated Aminosteroids for ophthalmic use
US5177064A (en) * 1990-07-13 1993-01-05 University Of Florida Targeted drug delivery via phosphonate derivatives
US5180716A (en) * 1990-08-01 1993-01-19 The Regents Of The University Of California Cyclodextrin complexes for neuraxial administration of drugs
US5827819A (en) * 1990-11-01 1998-10-27 Oregon Health Sciences University Covalent polar lipid conjugates with neurologically active compounds for targeting
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US5238927A (en) * 1990-11-30 1993-08-24 Brown Nesbitt D Hydrolytic stabilizer for unstable organic ions
US5668117A (en) * 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
US5221669A (en) * 1991-04-19 1993-06-22 The United States Of America As Represented By The Department Of Health And Human Services Antiviral compositions containing α-cyclodextrin sulfates alone and in combination with other known antiviral agents and glucocorticoids and methods of treating viral infections
EP0519428B1 (de) * 1991-06-21 2000-09-20 Takeda Chemical Industries, Ltd. Zyklodextrin-Zusammensetzung enthaltend Fumagillol-Derivate
US5446030A (en) * 1991-09-19 1995-08-29 Weisz; Paul B. Prevention of hemolysis
ATE156019T1 (de) * 1991-10-16 1997-08-15 Schering Corp Lipophile zusammensetzungen von oligosaccharid- antibiotikasalzen
IL103558A0 (en) 1991-10-30 1993-03-15 Schering Corp Tri-substituted tetrahydrofuran antifungals
US5206264A (en) * 1991-11-04 1993-04-27 Cypros Pharmaceutical Corporation Use of disulfiram to prevent cardiovascular damage
US5231089A (en) * 1991-12-02 1993-07-27 University Of Florida Method of improving oral bioavailability of carbamazepine
US5300280A (en) * 1992-02-14 1994-04-05 Mallinckrodt Medical, Inc. Stabilized radiopharmaceutical kits
RU2127733C1 (ru) * 1992-03-18 1999-03-20 Жансен Фармасетика Н.В. Стереоизомеры итраконазола или саперконазола, способ их получения, их комплексы и фармацевтическая композиция на их основе
US5552267A (en) * 1992-04-03 1996-09-03 The Trustees Of Columbia University In The City Of New York Solution for prolonged organ preservation
US5370989A (en) * 1992-04-03 1994-12-06 The Trustees Of Columbia University In The City Of New York Solution for prolonged organ preservation
US5602112A (en) * 1992-06-19 1997-02-11 Supergen, Inc. Pharmaceutical formulation
US20040014695A1 (en) * 1992-06-19 2004-01-22 Supergen, Inc. Pharmaceutical formulation
US5472954A (en) * 1992-07-14 1995-12-05 Cyclops H.F. Cyclodextrin complexation
US5324718A (en) * 1992-07-14 1994-06-28 Thorsteinn Loftsson Cyclodextrin/drug complexation
US5403828A (en) * 1992-08-13 1995-04-04 American Maize-Products Company Purification of cyclodextrin complexes
US5871710A (en) * 1992-09-04 1999-02-16 The General Hospital Corporation Graft co-polymer adducts of platinum (II) compounds
DE4239877C1 (de) * 1992-11-27 1994-03-17 Boehringer Ingelheim Int Stabilisierte Superoxid-Dismutase (SOD)-Zusammensetzung
US5684169A (en) * 1992-11-27 1997-11-04 Ensuiko Sugar Refining Co., Ltd. Cyclodextrin inclusion complex of taxol, and method for its production and its use
CA2150554A1 (en) * 1992-12-02 1994-06-09 Sheng-Wan Tsao Cyclodextrin and polymer based drug delivery system
US5494901A (en) * 1993-01-05 1996-02-27 Javitt; Jonathan C. Topical compositions for the eye comprising a β-cyclodextrin derivative and a therapeutic agent
US5298410A (en) * 1993-02-25 1994-03-29 Sterling Winthrop Inc. Lyophilized formulation of polyethylene oxide modified proteins with increased shelf-life
WO1994020136A1 (en) * 1993-03-08 1994-09-15 Department Of The Army, United States Government Cyclodextrin-peptide compositions
US6346518B1 (en) * 1993-03-10 2002-02-12 Janssen Pharmaceutica N.V. Itraconazole and saperconazole stereoisomers
ATE177635T1 (de) * 1993-04-22 1999-04-15 Senju Pharma Co Wässrige arzneizubereitungen enthaltend argatroban und cyclodextrin oder coffein
WO1995000177A1 (en) * 1993-06-17 1995-01-05 Dextran Products Limited Pharmaceutical preparation and a method for inhibiting the replication of various viruses
PH31594A (en) * 1993-09-30 1998-11-03 Janssen Pharmaceutica Nv Oral formulations on an antifungal.
ZA949182B (en) * 1993-12-02 1995-07-26 South African Druggists Ltd Pharmaceutical composition
FR2714066B1 (fr) * 1993-12-22 1996-01-12 Commissariat Energie Atomique Utilisation de mono-3,6-anhydrocyclodextrines pour solubiliser un composé hydrophobe et pour contrôler la pureté d'un énantiomère, et procédé de préparation de ces cyclodextrines.
US5646131A (en) * 1994-02-22 1997-07-08 The Arab Company For Drug Industries And Medical Applicances (Acdima) Method for solubilizing drugs using cyclodextrins and carboxylic acids
DE4414138A1 (de) * 1994-04-22 1995-10-26 Consortium Elektrochem Ind Acylierte gamma-Cyclodextrine
AU2701395A (en) * 1994-06-27 1996-01-19 General Hospital Corporation, The Graft co-polymer adducts of platinum (ii) compounds
US5631297A (en) * 1994-07-11 1997-05-20 Pate; David W. Anandamides useful for the treatment of intraocular hypertension, ophthalmic compositions containing the same and methods of use of the same
EP0777415A4 (de) * 1994-07-11 1999-06-16 David W Pate Zusammensetzungen, die ein anandamid-analoges enthalten, und sie verwendendes verfahren zur behandlung von erhöhtem augeninnendruck
ES2085832B1 (es) * 1994-07-22 1997-01-16 Rubio Lab Profarmacos de la 5,5-difenilhidantoina.
FR2726765B1 (fr) * 1994-11-14 1996-12-20 Cis Bio Int Compositions radiopharmaceutiques comprenant un complexe d'inclusion d'une cyclodextrine et d'un acide gras radiohalogene
US5861431A (en) * 1995-06-07 1999-01-19 Iotek, Inc. Incontinence treatment
US5679573A (en) * 1995-07-27 1997-10-21 Abbott Laboratories Stabilized aqueous steroid immunoassay standards with cyclodextrins
US7964598B2 (en) * 1995-10-17 2011-06-21 The J. David Gladstone Institutes ApoE4 domain interaction inhibitors and methods of use thereof
US5824668A (en) * 1996-11-07 1998-10-20 Supergen, Inc. Formulation for administration of steroid compounds
DE69736777T2 (de) * 1996-03-29 2007-08-23 Ortho-Mcneil Pharmaceutical, Inc. Amidinohydrazone als protease-inhibitoren
JP2000509374A (ja) 1996-04-19 2000-07-25 アルファ セラピュティック コーポレイション 凍結乾燥した血液タンパク質のウイルス不活性化方法
DK0912738T3 (da) 1996-05-22 2008-11-17 Viventia Biotech Inc Antigen-bindende-fragmenter der specifikt detekterer cancerceller, nukleotider der koder fragmenterne og anvendelse deraf til profylakse og detektion af cancere
US5906981A (en) * 1996-06-04 1999-05-25 Troy Corporation Halopropargyl inclusion complexes
US20050191661A1 (en) * 1996-11-06 2005-09-01 Tetsuya Gatanaga Treatment of inflammatory disease by cleaving TNF receptors
US6593456B1 (en) * 1996-11-06 2003-07-15 The Regents Of The University Of California Tumor necrosis factor receptor releasing enzyme
NZ335864A (en) 1996-11-06 2001-09-28 Univ California Isolated tumor necrosis factor receptor releasing enzyme (TRRE), compositions comprising the enzyme and methods of the use in modulation of TNF levels
HUP9700632A3 (en) * 1997-03-24 1999-10-28 Cyclolab Ciklodextrin Kutato F Pharmaceutical compositions containing propylamine derivative and cyclodextrine and process for producing the same
DE19713092A1 (de) * 1997-03-27 1998-10-01 Wacker Chemie Gmbh Komplexe aus Gamma-Cyclodextrin und Retinol bzw. Retinol-Derivaten sowie Verfahren zu ihrer Herstellung und ihre Verwendung
US7115722B1 (en) 1997-05-22 2006-10-03 Viventia Biotech, Inc. Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers
GB9712370D0 (en) * 1997-06-14 1997-08-13 Aepact Ltd Therapeutic systems
US6440933B1 (en) * 1997-09-10 2002-08-27 University Of Florida Compounds and method for the prevention and treatment of diabetic retinopathy
JP4087938B2 (ja) * 1998-02-04 2008-05-21 高砂香料工業株式会社 ヒノキチオ−ル類の分岐サイクロデキストリン包接化合物からなる抗菌剤およびそれを含有する組成物
US6344486B1 (en) 1998-04-03 2002-02-05 3-Dimensional Pharmaceuticals, Inc. Benzamide and sulfonamide substituted aminoguanidines and alkoxyguanidines as protease inhibitors
JP2003529528A (ja) 1998-04-24 2003-10-07 ３−ディメンショナル ファーマシューティカルズ， インコーポレイテッド プロテアーゼインヒビターとしてのアミノ酸アミジノヒドラゾン、アルコキシグアニジン、およびアミノグアニジン
US6046381A (en) * 1998-04-30 2000-04-04 The Regents Of The University Of California Apolipoprotein E transgenic mice and assay methods
US6325788B1 (en) 1998-09-16 2001-12-04 Mckay Douglas William Treatment of wound or joint for relief of pain and promotion of healing
US6207700B1 (en) 1999-01-07 2001-03-27 Vanderbilt University Amide derivatives for antiangiogenic and/or antitumorigenic use
US6762182B1 (en) 1999-01-07 2004-07-13 Vanderbilt University Converting cox inhibition compounds that are not COX-2 selective inhibitors to derivatives that are COX-2 selective inhibitors
MXPA01011956A (es) 1999-05-27 2002-06-21 Dimensional Pharm Inc Oxazaheterociclos como inhibidores de proteasas.
US6555139B2 (en) * 1999-06-28 2003-04-29 Wockhardt Europe Limited Preparation of micron-size pharmaceutical particles by microfluidization
WO2001004117A1 (en) 1999-07-09 2001-01-18 3-Dimensional Pharmaceuticals, Inc. Heteroaryl protease inhibitors and diagnostic imaging agents
US6306890B1 (en) 1999-08-30 2001-10-23 Vanderbilt University Esters derived from indolealkanols and novel amides derived from indolealkylamides that are selective COX-2 inhibitors
JP2003509409A (ja) 1999-09-13 2003-03-11 ３−ディメンショナル ファーマシューティカルズ， インコーポレイテッド アザシクロアルカノンセリンプロテアーゼ阻害剤
US6784165B1 (en) 1999-11-23 2004-08-31 Aderis Pharmaceuticals, Inc. Treatment of heart rhythm disturbances with N6-substituted-5′-(N-substituted) carboxamidoadenosines
TWI242015B (en) 1999-11-29 2005-10-21 Akzo Nobel Nv 6-mercapto-cyclodextrin derivatives: reversal agents for drug-induced neuromuscular block
AU4904101A (en) * 1999-12-08 2001-07-09 Fluoro Probe, Inc. Method for relieving pain associated with an internal disease site
AU2012101A (en) * 1999-12-20 2001-07-03 New Pharma Research Sweden Ab Veterinary compositions
EP1121940A1 (de) * 2000-01-31 2001-08-08 New Pharma Research Sweden AB Pharmazeutische zusammensetzungen mit einem antibiotikum und bromhexine, und verfahren zur ihrer herstellung
AU2001257022B2 (en) * 2000-04-13 2005-02-03 Mayo Foundation For Medical Education And Research Abeta 42 lowering agents
WO2001083520A2 (en) * 2000-05-02 2001-11-08 Theravance,Inc Polyacid glycopeptide derivatives
EP1278549B1 (de) * 2000-05-02 2008-12-10 Theravance, Inc. Zusammensetzung die eine zyklodextrin und ein glykopeptid-antibiotikum enthält
DE10029371A1 (de) * 2000-06-20 2002-01-03 Merck Patent Gmbh Heterocyclische Aminoalkylpyridinderivate als Psychopharmaka
US6872804B2 (en) * 2000-06-22 2005-03-29 Theravance, Inc. Glycopeptide disulfide and thioester derivatives
AU2001259816A1 (en) 2000-06-22 2002-01-02 Advanced Medecine, Inc. Polyhydroxy glycopeptide derivatives
UA75083C2 (uk) * 2000-06-22 2006-03-15 Тераванс, Інк. Похідні глікопептидфосфонатів
ES2302733T3 (es) * 2000-06-22 2008-08-01 Theravance, Inc. Derivados carboxi-sacaridos de glucopeptido.
US6476016B2 (en) * 2000-07-17 2002-11-05 3-Dimensional Pharmaceuticals, Inc. Cyclic oxyguanidine pyrazinones as protease inhibitors
EP1307432A1 (de) 2000-08-04 2003-05-07 3-Dimensional Pharmaceuticals, Inc. Zyklische oxyguanidin-proteasinhibitoren
PE20020300A1 (es) * 2000-08-22 2002-05-10 Pharmacia Corp Composicion de solucion de un farmaco antibiotico a base de oxazolidinona con mejoramiento de la carga de farmaco
EA200300473A1 (ru) * 2000-10-16 2003-08-28 Неофарм, Инк. Терапевтическая композиция на основе митоксантрона (варианты) и липидный препарат, способ его получения и способ лечения заболевания млекопитающего с его использованием
US20020146409A1 (en) * 2001-01-30 2002-10-10 Herring Steven W. Methods for stabilizing lyophilized blood proteins
US20030017207A1 (en) * 2001-05-01 2003-01-23 Lin Shun Y. Compositions and methods for treating vulvovaginitis and vaginosis
US20030064103A1 (en) * 2001-05-01 2003-04-03 Lin Shun Y. Compositions and methods for treating vulvovaginitis and vaginosis
US20060172007A1 (en) * 2001-05-01 2006-08-03 Nawaz Ahmad Compositions and methods for reducing vaginal pH
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7232924B2 (en) 2001-06-11 2007-06-19 Xenoport, Inc. Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7008934B2 (en) * 2001-06-28 2006-03-07 Baxter International Inc. Composition and method for reducing adverse interactions between phenothiazine derivatives and plasma using cyclodextrins
US6962944B2 (en) * 2001-07-31 2005-11-08 Arqule, Inc. Pharmaceutical compositions containing beta-lapachone, or derivatives or analogs thereof, and methods of using same
US7074824B2 (en) * 2001-07-31 2006-07-11 Arqule, Inc. Pharmaceutical compositions containing beta-lapachone, or derivatives or analogs thereof, and methods of using same
CA2463687A1 (en) 2001-10-18 2003-04-24 Decode Genetics Ehf Cyclodextrin complexes
US7045543B2 (en) 2001-11-05 2006-05-16 Enzrel Inc. Covalent conjugates of biologically-active compounds with amino acids and amino acid derivatives for targeting to physiologically-protected sites
US6881726B2 (en) * 2001-12-24 2005-04-19 Dow Pharmaceutical Sciences Aqueous compositions containing metronidazole
US20060105008A1 (en) * 2002-03-28 2006-05-18 Nawaz Ahmad Compositions and methods for reducing vaginal pH
WO2003086283A2 (en) * 2002-04-09 2003-10-23 Greenville Hospital System Metastasis modulating activity of highly sulfated oligosaccharides
PL372246A1 (en) * 2002-05-28 2005-07-11 3-Dimensional Pharmaceuticals, Inc. Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions
WO2003101358A1 (en) * 2002-05-31 2003-12-11 Titan Pharmaceuticals, Inc. Implantable polymeric device for sustained release of buprenorphine
US20030232091A1 (en) * 2002-06-17 2003-12-18 Adi Shefer Stabilized retinol for cosmetic dermatological, and pharmaceutical compositions, and use thereof
US6673792B1 (en) 2002-07-11 2004-01-06 Upchuck, Llc Broad-spectrum anti-emetic compositions and associated methods
DE60327225D1 (de) * 2002-08-20 2009-05-28 Bristol Myers Squibb Co Aripiprazol-komplex-formulierung und verfahren
WO2004026118A2 (en) * 2002-09-20 2004-04-01 Oregon Health & Science University Administration of free radical scavengers to prevent or treat ischemia-reperfusion injuries
AU2003302579B2 (en) * 2002-12-02 2008-09-18 Bharat Serums And Vaccines Ltd. Ifosfamide compositions for parenteral administration and a process for their preparation
WO2004071431A2 (en) * 2003-02-05 2004-08-26 Myriad Genetics, Inc. Method and composition for treating neurodegenerative disorders
EP1594512A4 (de) * 2003-02-11 2007-07-11 Kemia Inc Verbindungen zur behandlung von virusinfektionen
ZA200507877B (en) * 2003-03-31 2007-01-31 Titan Pharmaceuticals Inc Implantable polymeric device for sustained release of dopamine agonist
JP2006522809A (ja) 2003-04-10 2006-10-05 ３−ディメンショナル ファーマシューティカルズ， インコーポレイテッド 置換フェニルアセトアミおよびプロテアーゼインヒビターとしてのその使用
WO2004091630A1 (ja) * 2003-04-18 2004-10-28 Advanced Medicine Research Institute 眼に適用する疾患治療剤
US20060111318A1 (en) * 2003-04-18 2006-05-25 Advanced Medicine Research Institute Agent for treating eye diseases
US20050009776A1 (en) * 2003-04-24 2005-01-13 Aderis Pharmaceuticals, Inc. Method of treating atrial fibrillation or atrial flutter
US7157446B2 (en) * 2003-05-02 2007-01-02 Bristol Myers Squibb Company Complex of ras-farnesyltransferase inhibitor, a cyclodextrin, and ethanol
US7728036B2 (en) * 2003-05-20 2010-06-01 Erimos Pharmaceuticals, Llc Methods for delivery of catecholic butanes for treatment of tumors
US20070010573A1 (en) * 2003-06-23 2007-01-11 Xianqi Kong Methods and compositions for treating amyloid-related diseases
US7244764B2 (en) * 2003-06-23 2007-07-17 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US7414076B2 (en) * 2003-06-23 2008-08-19 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
AU2003903597A0 (en) * 2003-07-11 2003-07-24 Jakov Vaisman Treatment of premature ejaculation
US20050042284A1 (en) * 2003-07-11 2005-02-24 Myriad Genetics, Incorporated Pharmaceutical methods, dosing regimes and dosage forms for the treatment of Alzheimer's disease
US7488739B2 (en) * 2003-07-24 2009-02-10 Astellas Pharma Inc. Quinolone derivative or salt thereof
WO2005011617A2 (en) * 2003-07-31 2005-02-10 Ivax Corporation Transmucosal dosage forms for brain-targeted steroid chemical delivery systems
US7504401B2 (en) * 2003-08-29 2009-03-17 Locus Pharmaceuticals, Inc. Anti-cancer agents and uses thereof
WO2005025545A2 (en) * 2003-09-17 2005-03-24 Aderis Pharmaceuticals, Inc. Pharmaceutical formulation for controlled release of selodenoson
US20050074494A1 (en) * 2003-10-06 2005-04-07 Xiu-Xiu Cheng Itraconazole immediate release formulation
US20070020196A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid prepared from a unit dose suspension
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
BRPI0418276B8 (pt) 2003-12-31 2021-05-25 Cydex Pharmaceuticals Inc formulação líquida inalável compreeendendo budesonida
US20070020298A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether gamma-cyclodextrin and corticosteroid
DE102004011512B4 (de) 2004-03-08 2022-01-13 Boehringer Ingelheim Vetmedica Gmbh Pharmazeutische Zubereitung enthaltend Pimobendan
EP1730751B1 (de) * 2004-03-12 2009-10-21 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Magnetoresistives medium
EP1579862A1 (de) 2004-03-25 2005-09-28 Boehringer Ingelheim Vetmedica Gmbh Verwendung von PDE III Ihibitoren zur Reduktion der Herzgrösse in an Herzversagen leidenden Säugern
US8980894B2 (en) 2004-03-25 2015-03-17 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure
US20070293538A1 (en) * 2004-04-13 2007-12-20 Myriad Genetics, Incorporated Pharmaceutical Composition And Methods For Treating Neurodegenerative Disorders
US20050234018A1 (en) * 2004-04-15 2005-10-20 Allergan, Inc. Drug delivery to the back of the eye
DK3520779T3 (da) 2004-04-23 2022-03-21 Cydex Pharmaceuticals Inc DPI formulering indeholdende sulfoalkylethercyclodextrin
AU2005244770A1 (en) 2004-04-26 2005-12-01 Vanderbilt University Indoleacetic acid and indenacetic acid derivatives as therapeutic agents with reduced gastrointestinal toxicity
MXPA06012165A (es) * 2004-04-29 2007-01-17 Keystone Retaining Wall System Chapas para muros, muros de contencion y similares.
DE602005020796D1 (de) * 2004-07-22 2010-06-02 Bend Res Inc Geschmacksabdeckende formulierung mit einer retardierten wirkstoffformulierung und/oder schnell löslichem cyclodextrin
WO2006020853A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020852A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020850A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
US20080312201A1 (en) * 2004-09-10 2008-12-18 Patrick Fogarty Reduced Toxicity Methotrexate Formulations and Methods for Using the Same
ITMI20041763A1 (it) * 2004-09-16 2004-12-16 Altergon Sa Nuove formulazioni iniettabili contenenti progesterone
BRPI0517790A (pt) * 2004-11-12 2008-10-21 Neurochem Int Ltd métodos e composições fluoradas para tratar doenças relacionadas à amilóide
CN101103018A (zh) * 2004-11-16 2008-01-09 神经化学（国际）有限公司 治疗cns和淀粉样蛋白-相关疾病的化合物
RU2322450C2 (ru) * 2004-11-25 2008-04-20 Закрытое акционерное общество "Производственно-коммерческая Ассоциация АЗТ" Модифицированные 5'-фосфонаты азт в качестве активных компонентов для потенциальных противовирусных препаратов
CA2592320C (en) * 2004-12-22 2015-11-24 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
CA2595606C (en) * 2005-01-27 2014-12-16 Erimos Pharmaceuticals Llc Oral formulations for delivery of catecholic butanes including ndga compounds
US20070014833A1 (en) * 2005-03-30 2007-01-18 Sirtris Pharmaceuticals, Inc. Treatment of eye disorders with sirtuin modulators
JP2008542296A (ja) * 2005-05-25 2008-11-27 サートリス ファーマシューティカルズ， インコーポレイテッド サーチュイン活性化剤による眼障害の処置
US20060292099A1 (en) * 2005-05-25 2006-12-28 Michael Milburn Treatment of eye disorders with sirtuin modulators
CN101321742B (zh) 2005-05-26 2012-08-29 神经元系统公司 用于治疗视网膜疾病的组合物和方法
EP1898922A4 (de) * 2005-07-04 2012-03-14 Ramu Krishnan Verbessertes arzneimittel oder pharmazeutische verbindungen und eine zubereitung davon
WO2007014124A2 (en) * 2005-07-22 2007-02-01 Myriad Genetics, Inc. High drug load formulations and dosage forms
US20070191306A1 (en) * 2005-08-17 2007-08-16 Bristol-Myers Squibb Company FACTOR Xa INHIBITOR FORMULATION AND METHOD
EP1926703B1 (de) * 2005-09-20 2013-01-09 DSM IP Assets B.V. Neue dicarbonsäurederivate
DE602006015837D1 (de) * 2005-10-14 2010-09-09 Janssen Pharmaceutica Nv Formulierungen von tipifarnib zur intravenösen verabreichung
US7629331B2 (en) 2005-10-26 2009-12-08 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
PT1954292E (pt) 2005-11-28 2014-08-04 Verrow Pharmaceuticals Inc Composições úteis para reduzir a nefrotoxicidade e métodos para a sua utilização
US20070197486A1 (en) * 2005-12-20 2007-08-23 Verus Pharmaceuticals, Inc. Methods and systems for the delivery of corticosteroids
US20070249572A1 (en) * 2005-12-20 2007-10-25 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids
US20070160542A1 (en) * 2005-12-20 2007-07-12 Verus Pharmaceuticals, Inc. Methods and systems for the delivery of corticosteroids having an enhanced pharmacokinetic profile
US20070178049A1 (en) * 2005-12-20 2007-08-02 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids having an enhanced pharmacokinetic profile
US20070185066A1 (en) * 2005-12-20 2007-08-09 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids
US20070149480A1 (en) * 2005-12-23 2007-06-28 Alcon, Inc. PHARMACEUTICAL COMPOSITION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
EP1973524B1 (de) * 2006-01-06 2011-08-10 Intervet International BV Konzentrierte flüssige schilddrüsenhormonzusammensetzung
US20070191323A1 (en) * 2006-02-15 2007-08-16 Verus Pharmaceuticals, Inc. Stable corticosteroid mixtures
US7829584B2 (en) * 2006-03-21 2010-11-09 Janssen Pharmaceutica Nv Pyridines and pyridine N-oxides as modulators of thrombin
CN101466364A (zh) * 2006-03-22 2009-06-24 纽约大学西奈山医学院 鼻内施用氯胺酮治疗抑郁症
US20070232567A1 (en) * 2006-03-28 2007-10-04 Curtis Wright Formulations Of Low Dose Non-Steroidal Anti-Inflammatory Drugs And Beta-Cyclodextrin
AU2007230716B2 (en) 2006-03-28 2012-05-03 Javelin Pharmaceuticals, Inc. Formulations of low dose diclofenac and beta-cyclodextrin
US20070238789A1 (en) * 2006-03-31 2007-10-11 Chin-Ming Chang Prednisolone acetate compositions
US20070232556A1 (en) * 2006-03-31 2007-10-04 Montine Thomas J Methods and compositions for the treatment of neurological diseases and disorders
US7736624B2 (en) 2006-06-19 2010-06-15 Univ Vanderbilt Methods and compositions for diagnostic and therapeutic targeting of COX-2
US20080280891A1 (en) * 2006-06-27 2008-11-13 Locus Pharmaceuticals, Inc. Anti-cancer agents and uses thereof
WO2008006099A2 (en) * 2006-07-07 2008-01-10 Myriad Genetics, Inc. Treatment of psychiatric disorders
US20100316626A1 (en) * 2006-08-11 2010-12-16 The Government Of The United States Of America As Represented By The Secretary Methods for treatment and diagnosis of psychiatric disorders
US8178527B2 (en) * 2006-10-02 2012-05-15 Erimos Pharmaceuticals Llc Tetra-substituted NDGA derivatives via ether bonds and carbamate bonds and their synthesis and pharmaceutical use
US9067875B2 (en) 2006-10-02 2015-06-30 Erimos Pharmaceuticals Llc Tetra-substituted NDGA derivatives via ether bonds and carbamate bonds and their synthesis and pharmaceutical use
EP2862581B1 (de) 2006-10-12 2021-08-11 BHI Limited Partnership Verfahren, Verbindungen, Zusammensetzungen und Medien zur Abgabe von 3-Amino-1-Propanesulfonsäure
US8158609B1 (en) 2006-11-02 2012-04-17 Novartis Ag Use of cyclodextrins as an active ingredient for treating dry AMD and solubilizing drusen
EP1920785A1 (de) * 2006-11-07 2008-05-14 Boehringer Ingelheim Vetmedica Gmbh Pimobendan-Cyclodextrin Komplex enthaltendes flüssiges Präparat
US20110177161A1 (en) * 2007-05-24 2011-07-21 Dr. Reddy's Laboratories Limited Pharmaceutical compositions of [5(s)-(2'-hydroxyethoxy)-20(s)-camptothecin
US8054177B2 (en) * 2007-12-04 2011-11-08 Avaya Inc. Systems and methods for facilitating a first response mission at an incident scene using patient monitoring
AU2009223453B2 (en) 2008-03-03 2014-05-01 Tosk, Inc. Methotrexate adjuvants to reduce toxicity and methods for using the same
EP2342356A4 (de) 2008-09-29 2012-11-21 Univ Ben Gurion Amyloid-beta-peptidasen und verwendungsverfahren dafür
CN102223882B (zh) 2008-11-25 2016-02-03 贝林格尔.英格海姆维特梅迪卡有限公司 用于治疗肥厚型心肌病的III 型磷酸二酯酶(PPE III)抑制剂或Ca2+敏化剂
KR20110123789A (ko) * 2009-03-03 2011-11-15 알콘 리서치, 리미티드 리셉터 티로신 키나제 저해(ＲＴＫｉ) 화합물을 눈에 전달하기 위한 약학 조성물
KR20110130454A (ko) * 2009-03-03 2011-12-05 알콘 리서치, 리미티드 리셉터 티로신 키나제 저해(ＲＴＫｉ) 화합물을 눈에 전달하기 위한 약학 조성물
WO2010101989A1 (en) * 2009-03-03 2010-09-10 Alcon Research, Ltd. PHARMACEUTICAL COMPOSITION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
EP2238973A1 (de) 2009-04-07 2010-10-13 Cephalon France Lyophilisierte Präparate von Proteasominhibitoren
US11020363B2 (en) 2009-05-29 2021-06-01 Cydex Pharmaceuticals, Inc. Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same
US20100311838A1 (en) 2009-05-29 2010-12-09 Pipkin James D Injectable Melphalan Compositions Comprising a Cyclodextrin Derivative and Methods of Making and Using the Same
US20110042247A1 (en) * 2009-06-25 2011-02-24 Chandrasekhar Kocherlakota Formulations of azacitidine and its derivatives
WO2011103150A2 (en) 2010-02-18 2011-08-25 Cephalon, Inc. Lyophilized preparations of bendamustine
IT1400977B1 (it) 2010-07-01 2013-07-05 Euticals Spa Nuovi complessi di inclusione farmaceutici, solidi, solubili in acqua e le loro soluzioni acquose per uso orale, oftalmico, topico o parenterale, contenenti un macrolide ed alcune ciclodestrine.
US8410079B2 (en) 2010-08-06 2013-04-02 Island Kinetics Chirally correct retinal cyclodextrin hemiacetals for clarifying skin complexion
CA2816319C (en) 2010-11-01 2020-06-30 Marshall Edwards, Inc. Isoflavonoid compounds and methods for the treatment of cancer
NZ746605A (en) 2010-11-16 2020-05-29 Texas Heart Inst Agonists that enhance binding of integrin-expressing cells to integrin receptors
GB201021267D0 (en) * 2010-12-15 2011-01-26 Reckitt Benckiser Healthcare Int Ltd Novel pharmaceutical formulation
EP3345545B1 (de) 2011-04-21 2021-10-20 The Regents of The University of California Funktionalisierte magnetische nanoteilchen und ihre verwendung bei der abbildung von amyloider plaque und neurofibrillären bündeln
JP6320917B2 (ja) 2011-07-20 2018-05-09 ホスピーラ インコーポレイテッド 疼痛を治療する方法
EP3078374B1 (de) 2011-10-17 2019-06-19 Vanderbilt University Indomethacin-analoga zur behandlung von kastrationsresistentem prostatakrebs
FR2983858B1 (fr) * 2011-12-08 2014-01-03 Fabre Pierre Dermo Cosmetique Nouveaux composes inhibiteurs de la lipogenese
US10398705B2 (en) 2012-03-15 2019-09-03 Boehringer Ingelheim Vetmedica Gmbh Pharmaceutical tablet formulation for the veterinary medical sector, method of production and use thereof
ITMI20122027A1 (it) * 2012-11-28 2014-05-29 Altergon Sa Soluzioni acquose orali di ormoni steroidei e hp¿cd con biodisponibilità ottimizzata
AU2014209387B2 (en) 2013-01-23 2018-11-01 Aldeyra Therapeutics, Inc. Toxic aldehyde related diseases and treatment
KR102217616B1 (ko) 2013-03-15 2021-02-19 얀센 파마슈티카 엔.브이. S-케타민 하이드로클로라이드의 약제학적 조성물
JP6272475B2 (ja) 2013-07-19 2018-01-31 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハーＢｏｅｈｒｉｎｇｅｒ Ｉｎｇｅｌｈｅｉｍ Ｖｅｔｍｅｄｉｃａ ＧｍｂＨ 防腐エーテル化シクロデキストリン誘導体含有液体水性医薬組成物
DK3106150T3 (da) 2013-12-04 2021-11-01 Boehringer Ingelheim Vetmedica Gmbh Forbedrede farmaceutiske sammensætninger af pimobendan
EP3725307A1 (de) 2014-09-15 2020-10-21 Janssen Pharmaceutica NV Val66met (snp rs6265)-genotypspezifische dosierschemata und verfahren zur behandlung von depression
US20160095925A1 (en) * 2014-10-01 2016-04-07 Cadila Healthcare Limited Stable formulation of azacitidine or salts thereof and their process for preparation
WO2016126618A1 (en) 2015-02-02 2016-08-11 Mei Pharma, Inc. Combination therapies
KR20180073554A (ko) 2015-08-21 2018-07-02 알데이라 테라퓨틱스, 아이엔씨. 중수소화 화합물 및 이의 용도
US10426790B2 (en) 2016-02-28 2019-10-01 Aldeyra Therapeutics, Inc. Treatment of allergic eye conditions with cyclodextrins
US10537570B2 (en) 2016-04-06 2020-01-21 Boehringer Ingelheim Vetmedica Gmbh Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease
JP7116490B2 (ja) 2016-05-09 2022-08-10 アルデイラ セラピューティクス， インコーポレイテッド 眼の炎症性障害および疾患の組合せ処置
US10414732B2 (en) 2017-03-16 2019-09-17 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
US11110073B2 (en) 2017-03-24 2021-09-07 Cadila Healthcare Limited Storage stable aqueous injectable solution comprising diclofenac
US20230137562A1 (en) 2017-06-07 2023-05-04 Adrx, Inc. Tau aggregation inhibitors
EP3668886A2 (de) 2017-08-18 2020-06-24 Adrx, Inc. Peptidinhibitoren der tau-aggregation
AU2018348174A1 (en) 2017-10-10 2020-04-23 Aldeyra Therapeutics, Inc. Treatment of inflammatory disorders
CA3086478A1 (en) 2017-12-22 2019-06-27 Janssen Pharmaceuticals, Inc. Esketamine for the treatment of depression
US20210212944A1 (en) * 2018-06-07 2021-07-15 Pfizer Inc. Aqueous formulation comprising 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea
WO2020033344A1 (en) 2018-08-06 2020-02-13 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
CA3113462A1 (en) 2018-09-25 2020-04-02 Aldeyra Therapeutics, Inc. Formulations for treatment of dry eye disease
AU2019404930A1 (en) 2018-12-21 2021-06-03 Novartis Ag Oral formulations of branaplam
WO2020138421A1 (ja) * 2018-12-27 2020-07-02 国立大学法人熊本大学 脳移行性リガンド及び薬物担体
EP3934632A4 (de) 2019-03-05 2022-11-23 Janssen Pharmaceuticals, Inc. Esketamin zur behandlung von depression
JP2022526917A (ja) 2019-03-26 2022-05-27 アルデイラ セラピューティクス， インコーポレイテッド 眼科用製剤およびその使用
US11707443B2 (en) 2019-09-26 2023-07-25 Rk Pharma Inc. Storage stable aqueous parenteral solutions comprising diclofenac
CN113350286B (zh) * 2021-05-22 2022-07-26 南开大学 “水桥”介导超响应的功能协同两性离子脂质及其制备方法和应用
EP4233837A1 (de) 2022-02-24 2023-08-30 CellAct Pharma GmbH Feste und orale etoposid-toniribat-zusammensetzungen

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3459731A (en) * 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
US4024223A (en) * 1972-11-11 1977-05-17 Teijin Limited Stripe composition and method of reducing smell associated therewith
JPS53136513A (en) * 1977-05-06 1978-11-29 Ono Pharmaceut Co Ltd Stabilization of prostaglandin-x-related compounds
HU176215B (en) * 1978-01-27 1981-01-28 Chinoin Gyogyszer Es Vegyeszet Process for preparing a cyclodextrin-indomethacin inclusion complex with a ratio of at about 2:1
JPS54115368A (en) * 1978-03-01 1979-09-07 Ono Pharmaceut Co Ltd Prostaglandin i2 analog, its preparation, and drug composition containing it as active constituent
IT1113341B (it) * 1978-03-31 1986-01-20 Ono Pharmaceutical Co Analoghi della 6,9-metano-pgi2
US4352793A (en) * 1979-04-26 1982-10-05 Sumitomo Chemical Company, Limited Pharmaceutical composition comprising bencyclane fumarate and cyclodextrin
JPS6033430B2 (ja) * 1980-05-12 1985-08-02 小野薬品工業株式会社 プロスタグランジン類似化合物
EP0056995B1 (de) * 1981-01-23 1986-03-26 The Wellcome Foundation Limited Chemischer Komplex
HU183430B (en) * 1981-05-12 1984-05-28 Chinoin Gyogyszer Es Vegyeszet Process for producing cyclodextrine inclusion complexes of n-bracket-1-phenylethyl-bracket closed-3,3-diphenylpropylamine or n-bracket-1-phenylethyl-bracket closed-3,3-diphenylpropylamine-hydrochloride
US4407795A (en) * 1981-07-16 1983-10-04 American Cyanamid Company Inclusion compound of p-hexadecylamino benzoic acid in cyclodextrin and method of use
JPS5813541A (ja) * 1981-07-16 1983-01-26 Kureha Chem Ind Co Ltd エイコサペンタエン酸又はドコサヘキサエン酸のシクロデキストリン包接化合物
JPS5838250A (ja) * 1981-09-01 1983-03-05 Teikoku Chem Ind Corp Ltd 複合体
JPS58126810A (ja) * 1981-12-24 1983-07-28 Kaken Pharmaceut Co Ltd 抗炎症眼科用液剤およびその製法
US4383992A (en) * 1982-02-08 1983-05-17 Lipari John M Water-soluble steroid compounds
JPS58177949A (ja) * 1982-04-12 1983-10-18 Takeda Chem Ind Ltd ランカシジン群抗生物質包接化合物
US4659696A (en) * 1982-04-30 1987-04-21 Takeda Chemical Industries, Ltd. Pharmaceutical composition and its nasal or vaginal use
DE3315356A1 (de) * 1982-04-30 1983-11-17 Ono Pharmaceutical Co. Ltd., Osaka Verwendung von prostaglandinanalogen
US4727079A (en) * 1983-01-27 1988-02-23 University Of Florida Brain-specific dopaminergic activity involving dihydropyridine carboxamides, dihydroquinoline and isoquinoline carboxamides
EP0221588A3 (de) * 1982-05-18 1988-09-21 University Of Florida Gehirnspezifische Arzneimittelabgabe
US4479932A (en) * 1982-05-18 1984-10-30 University Of Florida Brain-specific drug delivery
US4829070A (en) * 1982-05-18 1989-05-09 University Of Florida Novel redox carriers for brain-specific drug delivery
US4824850A (en) * 1982-05-18 1989-04-25 University Of Florida Brain-specific drug delivery
US4540564A (en) * 1982-05-18 1985-09-10 University Of Florida Brain-specific drug delivery
US4425336A (en) * 1982-05-24 1984-01-10 Key Pharmaceuticals, Inc. 3,4-Dihydroxy-N-[3-(4-dihydroxyphenyl)-1-methyl-n-propyl]-beta-phenethylamine cyclodextrin complexes
JPS58213712A (ja) * 1982-06-07 1983-12-12 Nikken Kagaku Kk Ｐｐ−１４６６含有持続性製剤
US4424209A (en) * 1982-06-21 1984-01-03 Key Pharmaceuticals, Inc. 3,4-Di-isobutyryloxy-N- 3-(4-isobutyryloxyphenyl)-1-methyl-n-propyl!-beta-phenethylamine cyclodextrin complexes
JPS5920230A (ja) * 1982-07-19 1984-02-01 チバ−ガイギ−・アクチエンゲゼルシヤフト ピルプロフエン含有薬剤
HU190818B (en) * 1982-11-09 1986-11-28 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt,Hu Process for producing complexes of piperonyl-butoxide-cyclodextrin
HU194858B (en) * 1982-12-03 1988-03-28 Chinoin Gyogyszer Es Vegyeszet Process for producing dibenzo/b,d/pirane derivatives and pharmaceutical compositions containing them
JPS59104556A (ja) * 1982-12-07 1984-06-16 Sekisui Chem Co Ltd 蛋白質安定化剤
JPS6025967A (ja) * 1983-07-21 1985-02-08 Eisai Co Ltd トリパミド包接化合物
US4751095A (en) * 1983-07-28 1988-06-14 Karl Curtis L Aspartame stabilization with cyclodextrin
JPS6054384A (ja) * 1983-09-02 1985-03-28 Yamanouchi Pharmaceut Co Ltd 新規包接化合物およびその製造法
JPS6081166A (ja) * 1983-10-11 1985-05-09 Fujisawa Pharmaceut Co Ltd ２−ニトロオキシメチル−６−クロロピリジンのβ−シクロデキストリン包接化合物およびその製造法
US4546097A (en) * 1983-11-04 1985-10-08 The United States Of America As Represented By The Department Of Health And Human Services Saponin-based polyether polyols, pharmaceutical compositions and a method of using same
DE3346123A1 (de) * 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
IT1196033B (it) * 1984-02-22 1988-11-10 Chiesi Farma Spa Composto ad attivita' antiinfiammatoria ottenuto per complessazione con beta-ciclodestrina e relative formulazioni farmaceutiche
DE3574869D1 (de) * 1984-02-29 1990-01-25 Univ Florida Gehirnspezifische analoga von zentral wirksamen aminen.
US4675395A (en) * 1984-03-14 1987-06-23 Seiwa Technological Laboratories Limited Cyclodextrin inclusion compound and process for its preparation
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US4596795A (en) * 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
JPS6170996A (ja) * 1984-09-13 1986-04-11 Nikken Kagaku Kk マルトシル−α−サイクロデキストリンの製造方法
JPS61197602A (ja) * 1985-02-28 1986-09-01 Nikken Kagaku Kk 新規分岐サイクロデキストリンおよびその製造方法
JPS61207380A (ja) * 1985-03-11 1986-09-13 Taiyo Yakuhin Kogyo Kk モベンゾキサミンの経口製剤
GB8506792D0 (en) * 1985-03-15 1985-04-17 Janssen Pharmaceutica Nv Derivatives of y-cyclodextrin
JPS61236802A (ja) * 1985-04-13 1986-10-22 Nikken Kagaku Kk 新規な分岐γ―サイクロデキストリンの製造方法
JPS61286318A (ja) * 1985-06-13 1986-12-16 Ichiro Shibauchi 浴剤の製造方法
JPS623795A (ja) * 1985-06-28 1987-01-09 Tokuyama Soda Co Ltd 分枝状シクロデキストリンの製造方法
US4663316A (en) * 1985-06-28 1987-05-05 Warner-Lambert Company Antibiotic clathrates and pharmaceutical compositions thereof
US4728509A (en) * 1985-08-19 1988-03-01 Takeda Chemical Industries, Ltd. Aqueous liquid preparation
US4623641A (en) * 1985-09-09 1986-11-18 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara R.T. Method of treating ulcers and erosions in the gastrointestinal system using PGI2 -methyl ester-beta cyclodextrin inclusion complexes
US4617298A (en) * 1985-10-22 1986-10-14 University Of Florida Method and compositions for weight control
JPS62106901A (ja) * 1985-11-05 1987-05-18 Nikken Kagaku Kk ジグルコシル−β−サイクロデキストリンおよびその製造方法
JPH0635481B2 (ja) * 1986-01-14 1994-05-11 日研化学株式会社 ジグルコシル−α−サイクロデキストリンおよびその製造方法
JPS62281855A (ja) * 1986-05-29 1987-12-07 Daikin Ind Ltd ビタミン，ビタミン誘導体，またはホルモンを含有する包接化合物
GB8613688D0 (en) * 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
US4782070A (en) * 1986-07-01 1988-11-01 Fujisawa Pharmaceutical Co., Ltd. Cerebral dysfunction therapeutic agent, which comprises a dihydropyridine compound
JPS6327440A (ja) * 1986-07-18 1988-02-05 Sanraku Inc グルコシル化分岐シクロデキストリン含有組成物
JPS6336793A (ja) * 1986-07-31 1988-02-17 Nikken Kagaku Kk ジマルトシル―γ―サイクロデキストリンの製造方法
JPH0764884B2 (ja) * 1986-11-27 1995-07-12 株式会社トクヤマ シクロデキストリン組成物
JP2603240B2 (ja) * 1987-03-09 1997-04-23 バイエル薬品株式会社 ジヒドロピリジン−ヒドロキシプロピルシクロデキストリン包接複合体
US4888427A (en) * 1987-04-07 1989-12-19 University Of Florida Amino acids containing dihydropyridine ring systems for site-specific delivery of peptides to the brain

Also Published As

Publication number Publication date
AU619788B2 (en) 1992-02-06
US5024998A (en) 1991-06-18
JPH01294663A (ja) 1989-11-28
ZA889679B (en) 1990-08-29
AU618995B2 (en) 1992-01-16
IE883717L (en) 1989-06-30
ATE164855T1 (de) 1998-04-15
EP0327766B1 (de) 1998-04-08
IE64886B1 (en) 1995-09-20
ES2118707T3 (es) 1998-10-01
US4983586A (en) 1991-01-08
EP0327766A2 (de) 1989-08-16
JP3038715B2 (ja) 2000-05-08
AU2733988A (en) 1989-07-06
EP0327766A3 (de) 1990-09-26
CA1331564C (en) 1994-08-23
AU3176289A (en) 1989-07-27
US5002935A (en) 1991-03-26
DE3856160D1 (de) 1998-05-14

Similar Documents

Publication Publication Date Title
DE3856160D1 (de) Redoxsystem für auf das Gehirn gerichtete Arzneimittelabgabe
BG102894A (en) Aryl-heterocyclic salts-including complexes
DE69530785D1 (de) Cyclodextrine als suspendiermittel für pharmazeutische suspensionen
CA2127111A1 (en) A Method for Preparing Enteric-Coated Oral Drugs Containing Acid-Unstable Compounds
DK0831825T3 (da) Farmaceutiske formuleringer af stærkt lipofile camptothecinderivater
ES2177654T3 (es) Remedio contra la degeneracion espinocerebelosa.
ES8801580A1 (es) Un procedimiento para producir una solucion de glicosido de antraciclina exenta de pirogenos, esteril
FI924285A (fi) 4-desoxi-4-epipodophyllotoxinderivat eller ett farmaceutiskt acceptabelt salt daerav
IL141232A0 (en) Use of camptothecin derivatives, with reduced gastrointestinal toxicity
DE3752368D1 (de) Doxorubicin enthaltende einspritzbare gebrauchsfertige Lösungen gegen Krebs
AR018198A1 (es) Soluciones estables de mitoxantrona, procedimiento para prepararlas, utilizacion de dichas soluciones para la preparacion de medicamentos y losmedicamentos de aplicacion de dichas soluciones para el tratamiento de enfermedades cancerosas
FI892685A0 (fi) Menetelmä uusien, sytostaattisesti vaikuttavien antrasykliinijohdannaisten valmistamiseksi
NO923983L (no) Bisfenyletanderivater, fremgangsmaate for deres fremstilling og farmasoeytiske preparater derav
NO20010507L (no) Farmasoytisk sammensetning med antitumoraktivitet pa basis av karboplatin
MY106032A (en) New pharmaceutical compositions & new pharmaceutical products allowing the regeneration of leukocytes & their use in the treatment of acquired immuno-deficient syndrom
Akrawi Use of chronic portal vein infusion in rats to examine mephenytoin stereoselective disposition.
UA36163A (uk) Спосіб профілактики олігоануричної форми гострої ниркової недостатності
TH67352A (th) สูตรผสมสารเชิงซ้อนของอะริพิพราโซลและวิธีใช้
YU5301A (sh) Primena derivata kamptotecina sa smanjenom gastro-intestinalnom toksičnošću
UA36043A (uk) Спосіб лікування фетоплацентарної недостатності

Legal Events

Date Code Title Description
8364 No opposition during term of opposition